Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond
Current Hypertension Reports · 20.11.2026 · 28 (1)
DOI: 10.1007/s11906-026-01403-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Hypertension Reports, online erschienen am 20.11.2026. Verfasst von Chinenye C. Odo und 4 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose of Review Hypertension is the leading modifiable cardiovascular risk factor in the United States, with racially/ethnically diverse populations experiencing a disproportionate burden, associated with social, structural, and potentially biological determinants. This review examines how recently approved and investigational pharmacologic therapies and device-based interventions may advance hypertension control in 2026 and beyond, with deliberate attention to the strength and applicability of the available evidence in racially/ ethnically diverse populations. Recent Findings Aldosterone synthesis and mineralocorticoid receptor signaling represent important advances beyond the present guidelines for resistant hypertension and cardiovascular-kidney-metabolic risk reduction. For instance, baxdrostat, a recently approved aldosterone synthase inhibitor (ASI), has demonstrated clinically meaningful blood pressure reductions. In addition, lorundrostat, an investigational ASI, provides a model for racially representative trial design through the intentional enrollment of Black and Hispanic/Latino participants and consistent efficacy across racial subgroups. In contrast, pivotal finerenone trials demonstrated improved cardiac and renal outcomes but included limited representation of Black adults. Additional approved therapies include an agent targeting the endothelin pathway, aprocitentan, and device-based interventions via renal denervation therapy, although their effectiveness in diverse populations remains unknown. Therapies targeting natriuretic peptide signaling remain investigational but could potentially expand the therapeutic landscape. Summary Advances in antihypertensive therapy offer new opportunities to improve blood pressure control and reduce cardiovascular risk beyond the 2025 American Heart Association (AHA) and American College of Cardiology (ACC) AHA/ACC High Blood Pressure Guideline-directed approach. Ensuring equitable benefit from these innovations requires that therapeutic innovation be coupled with deliberate efforts to ensure equitable delivery and benefit across populations.
Zitieren
APA
Odo, C. C., Reddy, T., Ogunniyi, M. O., Ferdinand, K. C., & Ilonze, O. J. (2026). Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond. Current Hypertension Reports, 28(1). https://doi.org/10.1007/s11906-026-01403-5
Vancouver
Odo CC, Reddy T, Ogunniyi MO, Ferdinand KC, Ilonze OJ. Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond. Current Hypertension Reports. 2026;28(1). doi:10.1007/s11906-026-01403-5
BibTeX
@article{Odo2026,
author = {Odo, Chinenye C. and Reddy, Tina and Ogunniyi, Modele O. and Ferdinand, Keith C. and Ilonze, Onyedika J.},
title = {Addressing Disparities in Hypertension Control: The Potential Role of New Drugs and Devices in 2026 and Beyond},
journal = {Current Hypertension Reports},
year = {2026},
volume = {28},
number = {1},
doi = {10.1007/s11906-026-01403-5}
}
EUVIMED